The US Food and Drug Administration (FDA) has granted an approval to Medtronic's mySentry Remote Glucose Monitor.

mySentry is used in conjunction with the MiniMed Paradigm REAL-Time Revel System which is an insulin pump with built-in continuous glucose monitoring.

mySentry Remote Glucose Monitor facilitates parent or caregiver to view and monitor real-time insulin pump status and glucose trends, as well as hear alerts and alarms, while an adult or child with diabetes sleeps in his or her own room.

mySentry displays all the alerts and alarms available on the Paradigm Revel insulin pump including predictive alerts, continuous glucose monitoring (CGM) graph, insulin pump battery life, amount of insulin remaining, and time until the next glucose sensor calibration.

Yale Center deputy director and Pediatric Endocrinology chief William Tamborlane said advances in continuous glucose monitoring have given parents an added level of protection from dangerous nighttime hypoglycemia occurring in their sleeping child, as well as a means to improve their quality of life.